Prospective immunohistochemical analysis of BRAF V600E mutation in melanoma

摘要: The v-raf murine sarcoma viral oncogene homolog B1 (BRAF) V600E mutation is the most common activating genetic alteration of this and a predictive marker for therapeutic use BRAF inhibitors in melanoma. Our aim was to evaluate performance mutation-specific monoclonal antibody (VE1) prospective diagnostic setting melanoma patients (n = 102). All 41 cases (40.2%) that showed cyclic minisequencing analysis DNA were also initially scored immunopositive. Two as positive by immunohistochemistry negative DNA-based determined be immunonegative repeated staining with more representative specimens. Thus, detection using 100% sensitive 96.8% specific, when compared DNA. None V600K mutations detected VE1 7). However, rare V600E2 mutation. We studied role set who had been investigated sentinel node metastasis. Melanoma lymph metastases diagnosed 21.8% (12/55) nodes, immunopositivity 34.5% (19/55) cases. status did not correlate any clinicopathological parameters. In conclusion, specific method, which can used identify inhibitor-sensitive first-line method due its rapid affordable nature.